Torriden, the South Korean skincare brand built on its Dive-In hyaluronic acid line, grew revenue 47.5% in 2025 while operating profit grew 16.2%. When Goodai Global, the K-beauty group behind Beauty of Joseon and TIRTIR, arrived as a partner, it did not buy the company at the KRW 500 billion valuation that had circulated in the market (approx. USD 357 million at KRW 1,400/USD, the desk’s reference rate as of September 2026). It bought a sliver.
The question is whether each new won of revenue carries the profit the old won did. Torriden’s answer, so far, is no, and that answer explains the shape of the Torriden and Goodai Global deal better than any valuation headline.
The Deal
On July 29, 2026, Torriden and Goodai Global signed a memorandum of understanding for a strategic investment: no change of control, no brand merger. Per Korean media reports, Goodai Global is buying existing shares from Torriden’s founders and individual shareholders, who held 100% with no outside financial investor. The deal appears to be in progress; stake size and price have not been disclosed.
- Target: Torriden Inc., a private single-brand skincare company concentrated on the Dive-In hyaluronic acid line.
- Buyer: Goodai Global, owner of Beauty of Joseon, TIRTIR, SKIN1004, Round Lab and Skinfood, preparing a KOSPI listing targeted for early 2027.
- Form: minority secondary purchase (existing shares bought from current holders), with no new issuance reported.
- Prior process: LG H&H was reported in January 2026 to be reviewing an acquisition at a valuation of KRW 500 billion or more, then disclosed on May 19, 2026 that it would not proceed, citing differences over terms.
- Financials: 2024 revenue KRW 186.0 billion, operating profit KRW 52.0 billion (28.0% margin, as reported); 2025 revenue KRW 274.3 billion, operating profit KRW 60.4 billion (22.0%); 1H 2026 overseas revenue KRW 112.7 billion, 62% of sales, up 66.4% year on year.
The incremental arithmetic is the whole story. The KRW 88.3 billion of revenue added in 2025 produced KRW 8.4 billion of additional operating profit, an incremental margin of 9.5%, roughly one third of the 28% the existing business earned.
Structure Breakdown
Start with what kind of money this is. A secondary purchase leaves the company’s bank balance unchanged; the cash goes to existing shareholders. Had Torriden needed growth capital, it would have issued new shares. This is a partial liquidity event for the founders, not a capital raise.
Then read the sequence. A control sale was tried first and failed; about ten weeks later a minority sale took its place. LG H&H cited terms rather than price, but the market keeps results, not reasons: a KRW 500 billion figure and a failed deal now sit together in the disclosure record, and in the next negotiation that number is a ceiling, not a starting point.
Goodai Global paid KRW 600 billion in 2025 for Serin Company, Round Lab’s operator, about 24x its 2024 operating profit. Torriden, on the same 2024 basis, was discussed at about 9.6x, and its 2025 revenue was nearly three times Serin’s. One is a price agreed at the preferred-bidder stage and the other an unconfirmed ask, but the gap of more than 2.5x survives the caveat. What the market doubted was not the price but the denominator: whether KRW 60.4 billion of operating profit would still be there next year.
The doubt has addresses. Opening inventory shipped into new doors books exactly like consumer demand, and Torriden is reported to be in around 80,000 stores across 41 to 43 countries. Its 2025 export award for exports above USD 50 million (about KRW 70 billion) is not directly comparable, but its distance from estimated overseas revenue leaves open the possibility that part of that revenue moves through domestic export vendors. At home, Olive Young sales above KRW 100 billion at consumer prices against roughly KRW 68.4 billion of recognized domestic revenue imply the channel keeps around 30% of each consumer won, on the desk’s back-calculation.
At no layer, from Olive Young at home to Amazon, Sephora and Costco abroad, does Torriden set the toll. Its operating margin fell 5.94 percentage points in 2025: if that was a one-off investment in Sephora’s full US footprint and European pharmacies, margins recover and today’s buyer holds a cheap option; if it is structural dilution from the overseas mix, doubling revenue will not raise enterprise value. Public data cannot yet tell which.
The Governing Logic
Architects design not to win but to avoid losing. Why Goodai Global did not buy Torriden outright has not been disclosed, but capacity was not the constraint: in 3Q 2025 alone it executed close to KRW 1.6 trillion of related transactions, including a KRW 800 billion convertible bond and the Serin acquisition. That is intent, not budget. A minority stake buys observation and priority without a control premium; it is an option, and the point of an option is less to buy the upside than to cut off the downside.
The option has a second engine. Torriden has said it will accelerate overseas expansion on Goodai Global’s distribution network; the more distribution tilts toward the partner, the higher Torriden’s cost of leaving and the weaker its hand in any later negotiation. If the brand succeeds, Goodai can buy the rest of a locked-in asset on favorable terms; if it fails, the loss is capped at the stake.
This resembles Mutual Hostage Architecture, except the hostage runs one way; and unlike Proof-Deferred Pricing, it is the ownership, not the consideration, that waits for proof. The downside device is not a clause but the stake percentage itself: the most primitive hedge available, and the most certain.
The buyer learned this on its own books, recovering 77.6% when it sold Laka Cosmetics (bought for KRW 42.5 billion, sold for KRW 33.0 billion). With a KOSPI IPO targeted for early 2027 and intangibles reportedly near 60% of assets, a non-consolidated minority stake also adds the platform narrative without the balance-sheet weight of another consolidation. That the form suited the acquirer’s accounting more than the target’s needs cannot be ruled out.
Downside Protection
The desk modeled a financial investor on the same terms (10% for KRW 50 billion, no dividends, five-year exit, 20% illiquidity discount): roughly 1.67x and a 10.8% IRR in the base case, 55% of capital and an IRR of about -11% in the bear case. A control version with about 3x EBITDA of acquisition debt models at a 27-28% IRR, but about 89% of value creation comes from EBITDA growth, with multiple change contributing negatively. The largest single driver is margin: holding other inputs fixed, one percentage point moves enterprise value by about KRW 50 billion.
The structure therefore works only for a strategic buyer. Goodai Global can recover margin from volume moving through its own distribution even if the stake never pays a dividend; a financial investor cannot. Same price, same stake, same company, different return: the economics are set by the identity of the buyer.
What Must Be True
Three propositions carry the deal. Each comes with the observation that would falsify it.
1. The 2025 margin loss was a one-off build-out cost. Falsified if Torriden’s FY2026 operating margin holds near 22% or lower while the overseas share stays above 60%. The 9.5% incremental margin is then the business, revenue growth becomes value transferred to channels, and the asset reprices toward a distributor’s multiple.
2. Overseas growth is sell-through, not sell-in. Falsified if growth decelerates from roughly 50% toward the teens alongside rising inventory, returns and promotional spend. The compression multiplies: at a 22% margin, a 20% revenue decline paired with a five-point margin loss removes about 38% of operating profit. Shelf slots at Olive Young and Sephora, once lost, cost more to regain, because another brand, quite possibly one of Goodai Global’s own, already holds them.
3. Dive-In is not the only franchise. In the desk’s base-case DCF (enterprise value of KRW 778 billion), about 63.5% of value sits in the terminal value beyond year five, and that value currently rests on one ingredient line. Falsified if the announced soothing and firming lines and the Japan- and China-specific products fail to take a meaningful share of revenue.
The Architect’s Takeaway
If you were building your own deal room, the sequence transfers without capital: buy the piece rather than the whole, and lend a resource the other side lacks. First, locate the toll: map where money flows in your industry and identify who decides passage, whether a platform, a permitting office, a budget line or a channel. A brand can grow without limit and still keep little if it does not control the gate.
Second, take a minority position with your time. Enter a project at its single bottleneck and make that point unable to function without you. If the project fails, the loss is a fraction of your hours; if it succeeds, you hold priority in the next negotiation.
Third, plant switching costs. Send a structural read of one industry to a handful of people every week, unasked. Once they cite it in meetings, stopping it becomes their cost, and the relationship reverses direction.
Fourth, separate the risks a contract can transfer from those it cannot; escrow covers returns, not de-rating or gatekeeper policy. One employer or platform carrying all of your income is one serum line carrying two thirds of enterprise value, so keep at least two boards in play and know which exit path you hold that others do not.
Syndicate’s Note
Torriden’s 47.5% revenue growth was paid for with operating profit that grew 16.2%, and because no one could tell whether the lost margin was one-off or structural, the control deal died and the minority deal survived. The architect fixed the maximum loss first, built a structure the counterparty cannot easily leave, and let time decide the rest.
House Verdict: WATCH. Public information cannot yet separate a build-out cost from structural dilution, and the read turns on a single print. Falsifier: if Torriden’s audited FY2026 operating margin recovers toward 2024’s 28% while overseas revenue holds near 60% of sales, the 2025 compression was investment rather than dilution, and the market’s doubt about the denominator was misplaced. The verdict classifies structural learning value; it is not an investment judgment.
The desk proposes The Toehold Lock-in as a candidate for the Structure Pattern Library: a minority stake whose downside is capped by its size and whose upside is secured by switching costs planted through the buyer’s own infrastructure. It will be declassified when a second independent case appears.
FAQ
What is a secondary share purchase in private equity?
A secondary purchase buys existing shares from current holders rather than new shares from the company. The company’s balance sheet does not change; the cash goes to the selling shareholders, whereas a primary issue raises growth capital for the company itself.
Why did Goodai Global buy only a minority stake in Torriden?
The reasons have not been disclosed. Structurally, a minority stake caps the buyer’s loss at the size of the stake, while Torriden’s growing reliance on Goodai Global’s distribution network raises its cost of leaving. With 2025 profit growth of 16.2% lagging revenue growth of 47.5%, the durability of Torriden’s earnings remains unresolved.
How does Torriden’s valuation compare with Round Lab’s?
The KRW 500 billion figure discussed in January 2026 implies about 9.6x Torriden’s 2024 operating profit, against about 24x for Goodai Global’s acquisition of Round Lab operator Serin Company. One is an unconfirmed ask and the other a deal price, but the gap points to doubt about earnings durability rather than price.
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation. Figures are based on public reports and may be estimates.
For more structural insights and deep-dive video breakdowns, visit Structure Syndicate on YouTube.